Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01717963
Other study ID # 2011-002858-31
Secondary ID 204725-1
Status Completed
Phase Phase 3
First received
Last updated
Start date October 2012
Est. completion date April 30, 2018

Study information

Verified date October 2018
Source University of Oslo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Persons dependent on opioids like heroin, morphine, or codeine have a high risk of relapse, overdose and overdose death. This risk is elevated even further following discharge from treatment or correctional institutions where patients have been detoxified. At the moment, state-of-the-art treatment is based on maintaining the dependence on opioids by daily intake of opioid medications like methadone or buprenorphine. Recently, a medication containing the blocking agent naltrexone was approved in the US; this does not maintain dependence but instead blocks heroin and other opioids for 28 days after intramuscular administration. This study will conduct a 12-week randomized comparison of naltrexone intramuscular suspension (XL-NTX) with daily buprenorphine-naloxone in OMT. Medication will start preceding discharge from a treatment or correctional facility to participating catchment regions in Norway. The main hypotheses are that XL-NTX will do equally well as - or better than - OMT on the proportion of biological samples negative for opioids, retention, self-reported use of alcohol and illicit drugs. Following the 12-week randomized period, there will be a 36-week period where participants can receive the study medication of their choice. After the end of the study, data from national registry databases can be collected for a further 12 months on outcomes such as recidivism, mortality and morbidity.


Recruitment information / eligibility

Status Completed
Enrollment 166
Est. completion date April 30, 2018
Est. primary completion date August 31, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Opioid dependence (DSM-IV TR)

- Age 18 or above

- Applied & Approved for Norway's national OMT program

- Discharge within 30 days of inclusion from a controlled environment; e.g. inpatient treatment or correctional (prison) facility

- Voluntarily seeking treatment for opioid dependence

Exclusion Criteria:

- Pregnant or breast-feeding

- Acute or recurring severe psychiatric disorder, e.g. psychosis, suicidality

- Serious debilitation of liver or renal function (e.g. Child-Pugh level C)

- Use of excluded medication

- Known intolerance to study drugs or their ingredients

- Employment in firm manufacturing one of the study drugs or close relation to such person

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Naltrexone intramuscular suspension
A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
Buprenorphine-naloxone
Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).

Locations

Country Name City State
Norway Haukeland University Hospital Bergen Hordaland
Norway Akershus University Hospital Oslo Akershus
Norway Oslo University Hospital, Avdeling for Rus og Avhengighet Oslo
Norway Stavanger University Hospital Stavanger Rogaland
Norway Vestfold Hospital Trust Tonsberg Vestfold

Sponsors (10)

Lead Sponsor Collaborator
University of Oslo Haukeland University Hospital, Helse Stavanger HF, Norwegian Institute of Public Health, Oslo University Hospital, Ostfold Hospital Trust, The Hospital of Vestfold, The Research Council of Norway, The Royal Norwegian Ministry of Health, University Hospital, Akershus

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of biological samples negative/positive for opioid agonists Week 1-12 post discharge
Primary Retention Week 1-12 post discharge
Primary Days of use or abstinence from opioids Week 1-12 post discharge
Secondary Use of other substances of abuse Week 1-48
Secondary Mental health Self-reported mental health Week 1-12 or 1-48
Secondary Somatic health Self-reported and/or assessed by study personnel Week 1-12 or 1-48 post discharge
Secondary Psychosocial problems Psychosocial problems like recidivism, employment, family problems. Self-reported or registry-based. Week 1-12, Week 1-48, & Wk 49-100
See also
  Status Clinical Trial Phase
Recruiting NCT03675386 - Reducing Opioid Use for Chronic Pain Patients Following Surgery N/A
Completed NCT02593474 - Medication-Assisted Treatment for Youth With Substance Use Disorders Phase 1
Completed NCT02294253 - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone Phase 2/Phase 3
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Completed NCT01592461 - Starting Treatment With Agonist Replacement Therapies Follow-up Study N/A
Terminated NCT00768482 - A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence Phase 3
Completed NCT01741350 - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users N/A
Terminated NCT04121546 - Collaborative Care for Opioid Dependence And Pain Pilot Study N/A
Withdrawn NCT03368794 - Naloxone to TReatment Entry in the Emergency Setting N/A
Completed NCT03447743 - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder Early Phase 1
Completed NCT04464421 - SMART Effectiveness Trial N/A
Recruiting NCT04189523 - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage N/A
Completed NCT03305666 - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Phase 4
Recruiting NCT04003948 - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification Phase 2
Not yet recruiting NCT03813095 - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction Phase 2
Terminated NCT02935101 - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants Phase 2
Completed NCT01895270 - Improving Buprenorphine Detoxification Outcomes With Isradipine Phase 1/Phase 2
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4
Completed NCT01425060 - Improving Effective Contraceptive Use Among Opioid-maintained Women Phase 1
Completed NCT01262092 - Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals Phase 2